TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06075953

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: For premenopausal women: 20 mg or 5 mg tamoxifen orally for postmenopausal women: For postmenopausal women who are not tolerating an AI, investigators can change them to the low dose (5 mg) or standard dose (20 mg) of tamoxifen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: for postmenopausal women: standard oral doses of AI of choice: exemestane 25 mg daily, or reduced exemestane dosing: 25 mg 3 times per week orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: for postmenopausal women: standard oral doses of AI of choice: letrozole 2.5 mg daily,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrazole
Description: for postmenopausal women: standard oral doses of AI of choice: anastrozole 1 mg daily;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone + Anastrazole
Description: Investigational drug. Both pre- and post- menopausal subjects. 100mg testosterone in combination with 4mg anastrazole administered subcutaneously every 3 months for up to 3 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant
Description: Investigational drug. Both pre- and post- menopausal subjects. Elacestrant 400mg PO with food once daily up to 36 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-endoxifen
Description: Investigational drug. Both pre- and post- menopausal subjects. (z)-endoxifen 10mg delayed release capsule 1 hour before a meal or 2 hours after a meal once daily for up to 36 months.
Study: NCT05209165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: weekly Semaglutide (increased from starting dose of 0.25 mg at four-week intervals (0.5 mg, 1.0 mg, 1.7 mg) to a target dose of 2.4 mg) for 52 weeks with intake visit for the VA MOVE program

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo and intake visit for VA MOVE
Study: NCT06633614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supervised prehabilitation programme
Description: Participants will receive standard preoperative physiotherapy education along with a Fitbit Aspire 3 wearable device to track vital signs such as heart rate, physical activity, and sleep patterns. They will follow a personalized exercise program, supervised remotely by a physiotherapist via telemedicine twice a week. The program will include 20-minute sessions at least three times per week, focusing on strength training, aerobic exercises (at 40% of maximal heart rate), and flexibility exercises. Progress will be monitored through vital signs and workout data, with the physiotherapists adjusting the regimen as needed. Participants with low inspiratory pressure (MIP \&amp;lt;100 cmH₂O) will receive an Inspiratory Muscle Trainer (IMT). Additionally, some participants may be provided with a portable cycle pedometer featuring adjustable resistance. To ensure safety, both participants and caregivers will receive a safety briefing, and a 24-hour emergency hotline.
Study: NCT06632938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-382
Description: Subcutaneous (SC) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-382
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABBV-382
Description: IV Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABBV-382
Description: SC Injection
Study: NCT06632223

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory motor training
Description: Each session will be composed of 10 minutes of warm-up, followed by 50-60 minutes of sensory motor exercises, followed by 5-10 minutes of cool down.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy
Description: traditional physical therapy program in form of stretching exercises, strengthening exercises, scar management, and gait training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy
Description: traditional physical therapy program in form of stretching exercises, strengthening exercises, scar management, and gait training
Study: NCT05420714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom Professional Continuous Glucose Monitoring
Description: Patient will be asked to wear the Dexcom Pro-CGM device (small device that can be applied to either the arm or abdomen) for 10 days. They will have 30 minutes initial visit with CDCES to apply the device and review its use and 60 minute final session to review the blood sugar data from the CGM with CDCES and diabetes clinic provider.
Study: NCT05061108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAL2
Description: Community health worked based intervention to mitigate psychosocial and life circumstance barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education
Study: NCT05272137

Intervention type: DEVICE
Intervention: Evoke Spinal Cord Stimulation (SCS) System
Description: A spinal cord stimulation system that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
Study: NCT05648864

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viamigo
Description: Mobile application with the aim to enhance the independent outdoor mobility of the user while a coach (informal caregiver) can monitor the route from a distance.
Study: NCT05231577

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 7.5fr ultra-fine ureteroscopy
Description: The patient placed the lithotomy position, placed the ureteroscope to explore the affected ureter, retrogradely placed the guide wire, and placed the 12 / 14fr ureteral sheath under X-ray monitoring until the affected ureter was close to the outlet of the renal pelvis. Group 1 patients used 7.5fr ultra-fine ureteroscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 9.2fr Ureteroscopy
Description: The patient placed the lithotomy position, placed the ureteroscope to explore the affected ureter, retrogradely placed the guide wire, and placed the 12 / 14fr ureteral sheath under X-ray monitoring until the affected ureter was close to the outlet of the renal pelvis. Group 2 patients used 9.2fr Ureteroscopy
Study: NCT04913987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stryker Triathlon total knee replacement
Description: Knee arthroplasty using a standard care total knee.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zimmer Biomet Persona Partial Knee unicondylar knee replacement
Description: Knee arthroplasty using the Zimmer Biomet Persona Partial Knee (PPK).
Study: NCT06232460

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: H80
Description: 5g, 10g \& 20g
Study: NCT04644796

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline 0.9%
Description: Patients included in the placebo group will have their incisional site infused, targeting the paraspinal muscles with sterile saline at the end of their surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Patients included in the treatment group will have their incisional site infused, targeting the paraspinal muscles with liposomal bupivacaine at the end of their surgery.
Study: NCT05557461

Intervention type: DEVICE
Intervention: End-tifdal co2, systolic, diastolic blood pressure, ppv values and vci distensibility
Description: (0,1,3,5 minutes measurements will be taken) measured before and after the test will be recorded and compared.~Cardiac output and stroke volume variation, vci distensibility will be measured and recorded by a specialist cardiologist using siemens ocuson cv70 (Siemens AG Medical Solutions, Henkestrasse, the Germany) echocardiography before and after the test.

Intervention type: DEVICE
Intervention: End-tifdal co2, systolic, diastolic blood pressure, ppv values and vci distensibility
Description: (0,1,3,5 minutes measurements will be taken) measured before and after the test will be recorded and compared.~Cardiac output and stroke volume variation, vci distensibility will be measured and recorded by a specialist cardiologist using siemens ocuson cv70 (Siemens AG Medical Solutions, Henkestrasse, the Germany) echocardiography before and after the test.
Study: NCT04973124

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: These participants will receive intraoperative dexmedetomidine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: These participants will not receive intraoperative dexmedetomidine.
Study: NCT06391281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: The patient receiving hemodialysis treatment will be given fistula self-care training in 2 sessions. An educational booklet will be provided after the training.And routine care
Study: NCT04802239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical hypnosis group
Description: Hypnotic induction is performed according to a standard protocol and identical for all.~A script will be written to give all the important steps. .Only the pleasant place and the characteristics of the analgesic glove will be different between the subjects .the procedure will follow the following protocol:~* State of calm at rest of 3 minutes.~* Hypnotic induction by catalepsy of the eyes guided by breathing.~* The hypnosis session takes place in safety place , with glove protect by dissociation and confusion techniques.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: calm wake group
Description: healthy volunteers will observe 3 minutes calm waking state before standardized thermal harmful stimulation
Study: NCT06261554

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Low dose OIT
Description: Following the building-up phase (up to 14 months), patients will receive a daily low dose of sesame paste (300 mg sesame protein) mixed with well-tolerated fruit mousse or bread for 3 months (12 +/- 3 weeks).
Study: NCT05526495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing preoperative low-value test ordering
Description: A multi-component approach will be used:1) An administrative change will be implemented whereby medically necessary preoperative tests for patients undergoing non-urgent surgery will be ordered at the discretion of an anesthesiologist based on their clinical assessment. Adoption of the policy change will be facilitated by a local champion using an engagement and education program for anesthesiologists, surgeons, pre-admission clinic nurses and administrative staff; 2) The workshop program will include rationale for the policy, discussion of perceived local barriers to implementation and mitigation strategies. A train-the-trainer model will be used; 3) The departments will commit to supporting the change in policy. Nurses within preoperative clinic will be coached to feel comfortable calling the anesthesiologist about any pre-op tests ordered, and the Pre-Admission Unit will have the authority to cancel tests that deem unnecessary. Check boxes will be removed from medical order forms
Study: NCT06087107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Spinal Decompression Exercises
Description: The duration of the intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 40 minutes with 8-10 repetitions of each exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eldoa
Description: The duration of the intervention will be 4 weeks, 3 sessions a week, and a total of 12 sessions will be given to the study participants. Each session will last for 40 minutes.
Study: NCT06076057

Intervention type: DIAGNOSTIC_TEST
Intervention: vital signs monitoring
Description: Monitoring of vital signs using portable respiratory sleep monitors, NoxT3, carbon dioxide monitors, transcutaneous oxygen and carbon dioxide partial pressure monitors

Intervention type: DIAGNOSTIC_TEST
Intervention: vital signs monitoring
Description: Monitoring of vital signs using portable respiratory sleep monitors, NoxT3, carbon dioxide monitors, transcutaneous oxygen and carbon dioxide partial pressure monitors

Intervention type: DIAGNOSTIC_TEST
Intervention: vital signs monitoring
Description: Monitoring of vital signs using portable respiratory sleep monitors, NoxT3, carbon dioxide monitors, transcutaneous oxygen and carbon dioxide partial pressure monitors

Intervention type: DIAGNOSTIC_TEST
Intervention: vital signs monitoring
Description: Monitoring of vital signs using portable respiratory sleep monitors, NoxT3, carbon dioxide monitors, transcutaneous oxygen and carbon dioxide partial pressure monitors

Intervention type: DIAGNOSTIC_TEST
Intervention: vital signs monitoring
Description: Monitoring of vital signs using portable respiratory sleep monitors, NoxT3, carbon dioxide monitors, transcutaneous oxygen and carbon dioxide partial pressure monitors

Intervention type: DIAGNOSTIC_TEST
Intervention: vital signs monitoring
Description: Monitoring of vital signs using portable respiratory sleep monitors, NoxT3, carbon dioxide monitors, transcutaneous oxygen and carbon dioxide partial pressure monitors

Intervention type: DIAGNOSTIC_TEST
Intervention: vital signs monitoring
Description: Monitoring of vital signs using portable respiratory sleep monitors, NoxT3, carbon dioxide monitors, transcutaneous oxygen and carbon dioxide partial pressure monitors
Study: NCT06197854

Intervention type: PROCEDURE
Intervention: Hernioplasty
Description: Surgical hernioplasty

Intervention type: PROCEDURE
Intervention: Hernioplasty
Description: Surgical hernioplasty
Study: NCT04980690

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBC0966
Description: IBC0966 is an investigational product.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBC0966
Description: IBC0966 is an investigational product.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBC0966
Description: IBC0966 is an investigational product.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBC0966
Description: IBC0966 is an investigational product.
Study: NCT05636384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based care
Description: Home-based medical care is based on a specialized home-based medical team approach, including following:~1. Specialized Home-Based Medical Team Approach~2. Initial Assessment and Education~3. Initial Home Visits and Education~4. Multidisciplinary Team Meeting~5. Regular Assessment After the Initial Visit
Study: NCT05783076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy
Description: Details have been shown in arm descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adoptive cell therapy with vNKT cells
Description: Details have been shown in arm descriptions.
Study: NCT05480436

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: coadministration
Description: the coadministration of an inactivated COVID-19 vaccine (BBIBP-CorV) and IIV4 on Day 0, and the coadministration of BBIBP-CorV and PPV23 on Day 28

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 vaccine
Description: received two doses of inactivated COVID-19 vaccine (BBIBP-CorV)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IIV4+PPV23
Description: received one dose of IIV4 on Day 0, and one dose of PPV23 on Day 28
Study: NCT04980690

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBC0966
Description: IBC0966 is an investigational product.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBC0966
Description: IBC0966 is an investigational product.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBC0966
Description: IBC0966 is an investigational product.
Study: NCT04359433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise programme
Description: Exercise programme includes 8 anaerobic movements choosen from Tabata. This exercise programme workout is aimed at body fat reduction, and the structure is as follows:~* 8 anerobic movements in 20 seconds is a set~* Rest for 10 seconds before another set~* Finish 4 sets every time, it shall take you 4 minutes~* Do 4 sets 2 to 3 times a week
Study: NCT04519151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg administered by IV infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 20 mg administered orally (PO) QD during each 21-day cycle.
Study: NCT05076526

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid (Synolis VA)
Description: Synolis VA harbours the following characteristics:~* NaHA (Sodium hyaluronate): 20mg/mL, biofermantative and pharmaceutical grade origin.~* Sorbitol: 40mg/mL~* Molecular weight of 2MDa, sterilized in moist heat

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellular Matrix platelet-rich-plasma with hyaluronic acid (CM PRP-HA)
Description: The CM-PRP-HA tube is under vacuum containing the following:~* 2mL of hyaluronic acid gel in phosphate buffer (Sodium chloride, Dipotassium hydrogenphosphate, Potassium dihydrogenphosphate, Potassium chloride and water for injection). Not crosslinked Hyaluronic Acid (40mg per tube) is obtained from fermentation~* 3g of inert cell-selector gel~* 0.6mL of anticoagulant (sodium citrate 4%)
Study: NCT05948254

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Triple function scan body
Description: The scan bodies were used to scan the implant position, Jaw registration and facial scan alignment, First of all scan bodies were selected according to vertical dimension of occlusion, then the emergence profile together with the selected scan body were scanned,All scan bodies were then removed from the patient mouth except one or even two that were scanned in the jaw scan step, this scan body was utilized as a stopper, the patient was asked to bite until the scan body came in contact with the lower or upper teeth in case of edentulous upper or lower arch respectively, scan body in place (in the same orientation of the previous jaw scan ) provided that at least the tip of the scan body appeared when the patient is asked to smile which would be used as a common area so that the intra oral scanner can relate the jaw scan to the lips and face.
Study: NCT06466122

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT05830292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diffuse reflectance spectroscopy (DRS) probe
Description: The spectroscopic DRS probe, either sterilised or covered with a sterile probe cover, will be used on the tissue as part of the patient's operation, inside the body itself.
Study: NCT04960150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Press tack needle
Description: Press tack needle acupuncture using Seirin Pyonex sized 0.20x1.2mm

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Plesterin
Description: Plesterin
Study: NCT06500988

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Corrie Virtual Atrial Fibrillation Management Program
Description: Intervention aims to implement a comprehensive digital atrial fibrilation guideline-recommended toolkit
Study: NCT04474847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Participants randomized to abatacept will receive abatacept 125 mg administered by subcutaneous injection once a week. Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 3 will have the option of entering an open-label trial period whereby they would receive open-label abatacept for up to 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to placebo will receive a sterile placebo solution administered by subcutaneous injection once a week. Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 3 will have the option of entering an open-label trial period whereby they would receive open-label abatacept for up to 12 months.
Study: NCT04914104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training - Headspace App
Description: The intervention group will receive free access to the mobile app Headspace and directed to access the app three times a week for at least 15 minutes.
Study: NCT06131307

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Education
Description: Paternalistic leadership training will be given to clinical manager nurses.
Study: NCT05728307

Intervention type: DEVICE
Intervention: neoGuard vital signs monitor
Description: The neoGuard device is a 4-in-1 wearable vital signs monitor developed by Neopenda, PBC (Chicago, Illinois). The system is designed to continuously measure temperature, pulse rate (PR), respiratory rate (RR) and blood oxygen saturation (SpO2). It contains two non-invasive sensors: an optical reflectance pulse oximeter and a digital temperature sensor. These sensors measure signals from the surface of the patient's skin, and algorithms within the device calculate the pulse rate, respiratory rate, SpO2 and temperature.~The device is made of medical grade polyetherimide plastic and can be worn on the forehead through an adjustable band. The PR, RR, temperature and SpO2 data are collected, recorded and transmitted via Bluetooth Low Energy (BLE) to a tablet which can be placed within a range of 20-30 meter distance. The neoGuard technology has received CE mark certification and is also registered with the Kenya Pharmacy and Poisons Board (KPPB).
Study: NCT04977908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CamAPS HX
Description: Fully automated closed-loop system (CamAPS HX) with ultra-rapid Lispro insulin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard insulin pump therapy with CGM
Description: Participants usual insulin pump therapy with Dexcom G6 CGM